Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030.

IA2030 Innovation Research Vaccines

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
16 Dec 2022
Historique:
received: 19 04 2021
revised: 08 06 2022
accepted: 17 11 2022
entrez: 18 12 2022
pubmed: 19 12 2022
medline: 19 12 2022
Statut: aheadofprint

Résumé

Research and innovation have been fundamental to many of the successes in immunization thus far, and will play important roles in the future success of Immunization Agenda 2030 (IA2030). Strategic Priority 7 (SP7) of IA2030, which addresses research and innovation, is explicitly informed by country needs and priorities, and aims to strengthen the innovation ecosystem through capacity building and collaboration at country, regional, and global levels. SP7 identifies four key focus areas: (1) "needs-based innovation", (2) "new and improved products, services, and practices", (3) "evidence for implementation", and (4) "local capacity". Strategic interventions in these key focus areas apply the lessons of the Global Vaccine Action Plan and the "Decade of Vaccines" to emphasize local innovation, promote the use of research by countries to improve program performance and impact, and encourage capacity building for the development and implementation of innovations. The proposed approach will maintain a focus on the development of new vaccines and the improvement of existing vaccines, and increase attention to innovation in service delivery. Monitoring and evaluation will foster evidence-based priority setting at the country level and help to ground the global research and development (R&D) agenda in the needs of communities. Together, these approaches are intended to harness the power of research and innovation more effectively, to meet the challenges of the future and achieve the ambitious goals of IA2030.

Identifiants

pubmed: 36529593
pii: S0264-410X(22)01454-2
doi: 10.1016/j.vaccine.2022.11.041
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

David Sarley (D)

Bill & Melinda Gates Foundation, Seattle, WA, USA.

Angela Hwang (A)

Consultant, Albany, CA, USA. Electronic address: angela@ahwang.net.

B Fenton Hall (B)

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Andrew Ford (A)

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Birgitte Giersing (B)

World Health Organization, Geneva, Switzerland.

David C Kaslow (DC)

PATH, Seattle, WA, USA.

Brian Wahl (B)

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.

Martin Friede (M)

World Health Organization, Geneva, Switzerland.

Classifications MeSH